Back to results
US 2014/0193333 A1Published application
Therapeutic and diagnostic target
AssigneeOxford Biotherapeutics Ltd
InventorsChristian Rohlff, Alasdair Stamps
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOxford Biotherapeutics Ltd
InventorsChristian Rohlff, Alasdair Stamps
Estimating the term…
The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.
(canceled)
A method for the treatment or prophylaxis of disease wherein BST1 is expressed in said disease, which comprises administering to a subject in need thereof a therapeutically effective amount of an affinity reagent which binds to BST1.
(canceled)
(canceled)
(canceled)
(canceled)
A method of detecting, diagnosing and/or screening for or monitoring the progression of disease wherein BST1 is expressed in said disease, or of monitoring the effect of a drug or therapy wherein BST1 is expressed in said disease, in a subject which comprises detecting the presence or level of BST1, or one or more fragments thereof, or the presence or level of nucleic acid encoding BST1 or which comprises detecting a change in the level thereof in said subject.
A method of detecting, diagnosing and/or screening for or monitoring the progression of a disease wherein BST1 is expressed in said disease, or of monitoring the effect of a drug or therapy wherein BST1 is expressed in said disease, in a subject which comprises detecting the presence or level of antibodies capable of immunospecific binding to BST1, or one or more fragments thereof.
A method for identifying an agent for the treatment or prophylaxis of disease wherein BST1 is expressed in said disease, wherein the method comprises (a) contacting BST1, or one or more fragments thereof, with a candidate agent;
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.